- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00980252
Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Overview: Many people recovering from first-episode schizophrenia typically respond very well to their initial course of antipsychotic medications; however, studies indicate that nonadherence rates soar as high as 90% in the first year and do not improve over time. To date, there is no effective psychosocial intervention that improves adherence or reduces the adverse consequences of nonadherence after it occurs. Thus, it is imperative to develop a new intervention to improve medication adherence and improve clinical outcomes in patients recovering from first-episode schizophrenia.
This study is to pilot an intervention specifically suited for patients with first-episode schizophrenia based on the principles of Cognitive Behavioral Therapy (CBT). This is to focus on adherence from the perspective of the patient.
Methods: This study compares the effectiveness of a standard psychoeducation program [Team Solutions (TS)] to a CBT approach known as the Health Dialogue Intervention (HDI). Consenting patients will receive a 4 week stabilization assessment period and then be randomized to a prospective, random-assignment study comparing the effectiveness of TS to HDI to improve medication adherence of patients recovering from first-episode schizophrenia.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60612
- University of Illinois at Chicago
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
There is a 2 step inclusion/exclusion criteria, the first being for assessing overall eligibility to enter the study, and then, for continued outpatient treatment for schizophrenia, schizophreniform disorder, or schizoaffective disorder.
Inclusion criteria for entry into the Evaluation Phase:
- Between 16-45 years of age
- A provisional clinical diagnosis of schizophreniform disorder, schizophrenia, or schizoaffective disorder in last 6 months
- Discharge from inpatient unit for treatment of psychotic symptoms must have occurred in the last 6 months, or, if never hospitalized, initial treatment started in the last 6 months
- Able to fully participate in the informed consent process
- The patient is judged to be an appropriate candidate for ongoing outpatient follow-up at the First-episode Treatment Program at the Psychotic Disorders Program at UIC
Exclusion criteria for the Evaluation Phase:
- Unable to understand informed consent process
- A history of nonresponse to prior antipsychotic trials such that long-term inpatient treatment or clozapine will be recommended
- Prior treatment with clozapine
- Discharge from inpatient treatment for psychotic symptoms, initial treatment, or provisional diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform occurred more than 6 months from enrollment into the evaluation phase
- Pregnancy or stated goal to become pregnant
- Will not be living close enough to the medical center to return for follow-up visits or assessments
- History of geographic instability such that it is judged unlikely that patient will reside in the area
- Currently under arrest for a felony, or an arrest is deemed likely in the near future
- Currently receiving medication over objection by court order
- Currently receiving treatment in another research protocol
Inclusion Criteria for the Treatment Intervention Phase:
- Willingness to transition to receive evaluation and future pharmacologic treatment at the Psychotic Disorders Program at UIC
- Has capacity to understand the risks and benefits of participating in a randomized psychosocial trial
- Willingness to sign informed consent to go into the Treatment Intervention Phase
- Is able to complete a post-test for understanding the nature of the study and what it entails, and the potential risks and benefits of study participation
- Is willing to have therapy sessions recorded for fidelity assessments
- Is willing to receive follow-up independent assessments of adherence status, including separate interviews with trained independent raters, and our contacting the outpatient pharmacy for pharmacy refill records
Exclusion criteria for Treatment Intervention Phase:
- Diagnosis or inpatient treatment for psychotic symptoms occurred more than 6 months from date of enrollment into evaluation phase
- Acutely psychotic individuals may not participate because therapy will not benefit if symptoms are too severe
- Has dropped out of the treatment program and cannot be located for follow-up appointments
- Stated refusal to come for to at least one clinical evaluation appointment at the PDP, or has been a "no show" for at least three consecutive appointments
- Judged to be at significant and imminent risk of harm to self or others*
- Ongoing active substance or alcohol use that is not controlled during the Evaluation Phase, along with refusal of referral to a "dual diagnosis" treatment program for substance abuse problems
- Remains enrolled in another research protocol at UIC*
- Unwilling to consider any additional psychotherapeutic intervention above and beyond coming in to the service for medication management appointment
- Baseline PANSS total score ≥ 90, or has a individual PANSS item of conceptual disorganization (item P2), excitement (P4), or hostility (P7) that is ≥ 5 (moderately severe)*
- Judged to require additional concrete case management services to support medication adherence*
- Receives antipsychotics under coercive conditions (e.g. inpatient or outpatient commitment)*
Note: The exclusion criteria (*) may be present during some parts of the Evaluation Phase and would need to be resolved within the 4 week time period permitted for the Evaluation Phase prior to the Treatment Intervention Phase of study entry.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
---|---|
Sperimentale: CBT
UK-based intervention
|
Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
1. Acceptance of therapeutic intervention as measured by number of sessions attended. 2. Difference in adherence behavior as measured by duration of antipsychotic treatment during follow up (ASV). 3. Differences in adherence attitudes (ROMI).
Lasso di tempo: Completion of Study
|
Completion of Study
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
1. Compare the course of symptoms and relapse of patients in HDI to those in the TS.
Lasso di tempo: Completion of Study
|
Completion of Study
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Peter J. Weiden, M.D., University of Illinois at Chicago
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- R34MH080978 (Sovvenzione/contratto NIH degli Stati Uniti)
- R34MH080978-01A2 (Sovvenzione/contratto NIH degli Stati Uniti)
- DSIR 83-AT
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cognitive Behavioral Therapy
-
Ontario Shores Centre for Mental Health SciencesMindbeaconRitiratoDisturbo depressivo maggiore
-
University of PittsburghReclutamentoDistrofia muscolare di DuchenneStati Uniti
-
Sarah MorrowLawson Health Research InstituteCompletato
-
Assuta Hospital SystemsTel Aviv UniversityCompletato
-
Weill Medical College of Cornell UniversityReclutamentoDepressione perinatale | Ansia perinataleStati Uniti
-
Karadeniz Technical UniversityCompletatoEmodialisi | Solitudine | Felicità | Adattamento | Terapia assistita da animali | SintomoTacchino
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Reclutamento
-
Zealand University HospitalUniversity of Copenhagen; Technical University of Denmark; OptoCeuticsCompletatoMalattia di AlzheimerDanimarca
-
Florida International UniversityNon ancora reclutamentoSindrome da deficit di attenzione e iperattivitàStati Uniti
-
University of AmsterdamAcademic Center for Trauma and Personality; Arkin Mental Health CareIscrizione su invitoDisturbo borderline di personalitàOlanda